Prosecution Insights
Last updated: October 01, 2026
Application No. 17/352,771

LOCAL ACTIVATION TIME ANALYSIS SYSTEM

Non-Final OA §101
Filed
Jun 21, 2021
Priority
Sep 14, 2020 — provisional 63/077,780
Examiner
MALAMUD, DEBORAH LESLIE
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Biosense Webster (Israel) Ltd.
OA Round
5 (Non-Final)
78%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allowance Rate
685 granted / 876 resolved
+8.2% vs TC avg
Moderate +10% lift
Without
With
+9.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
40 currently pending
Career history
906
Total Applications
across all art units

Statute-Specific Performance

§101
9.0%
-31.0% vs TC avg
§103
31.4%
-8.6% vs TC avg
§102
45.0%
+5.0% vs TC avg
§112
11.9%
-28.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 876 resolved cases

Office Action

§101
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 29 June 2026 has been entered. Claims 1-9 and 20 are withdrawn; claims 10-19 are pending. Response to Arguments Applicant’s arguments, see “Remarks”, filed 29 June 2026, with respect to the rejection under 35 USC 101 as directed to an abstract idea without significantly more have been fully considered and are persuasive. The rejection of claims 10-19 has been withdrawn. However, Applicant's arguments filed 29 June 2026, with regards to the rejection of claims 10-19 under 35 USC 101 as encompassing a human organism have been fully considered but they are not persuasive. The Applicant argues (pages 19-20, “Remarks”): Section 33(a) is directed to claims that are themselves human organisms, such as human embryos and clones; it is not directed to system claims that merely refer to a person in describing the source of input data... Taken as a whole, claim 10 is a server-based signal-processing system; it is not a person. The phrase "manually annotated by respective annotation personnel" describes the provenance of the training data, namely, how the local activation time annotations came into existence before being received by the remote server. The personnel are not elements of the claimed system; they are the historical source of the annotations. A system claim that recites receiving "user input" does not thereby claim the user, and a method claim that recites a "sample obtained from a patient" does not thereby claim the patient. Likewise, claim 10's reference to annotation personnel as the source of historical annotations does not bring the personnel within the scope of the claim. The claimed invention as a whole is the server-based signal-processing system, not a human organism. The Examiner respectively disagrees with this assessment. The claims explicitly require the manual annotation by one or more annotation personnel as part of the inventive system. The claims should be amended to specify that is the collected data that is sent to the server, not the manual annotations, to preclude the system as encompassing a human or humans as part of the inventive system. Claim Rejections - 35 USC § 101 Section 33(a) of the America Invents Act reads as follows: Notwithstanding any other provision of law, no patent may issue on a claim directed to or encompassing a human organism. Claims 10-19 rejected under 35 U.S.C. 101 and section 33(a) of the America Invents Act as being directed to or encompassing a human organism. See also Animals - Patentability, 1077 Off. Gaz. Pat. Office 24 (April 21, 1987) (indicating that human organisms are excluded from the scope of patentable subject matter under 35 U.S.C. 101). Claim 10 requires “annotation personnel” throughout the claim. As previously noted, these personnel explicitly refer to humans in the Specification of the instant application. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DEBORAH L MALAMUD whose telephone number is (571)272-2106. The examiner can normally be reached Mon - Fri 1:00-9:30 Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Unsu Jung can be reached at (571) 272-8506. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DEBORAH L MALAMUD/Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Show 8 earlier events
Mar 12, 2026
Response after Non-Final Action
Mar 12, 2026
Response Filed
Mar 25, 2026
Response Filed
Apr 14, 2026
Final Rejection mailed — §101
Jun 15, 2026
Response after Non-Final Action
Jun 29, 2026
Request for Continued Examination
Jul 09, 2026
Response after Non-Final Action
Jul 21, 2026
Non-Final Rejection mailed — §101 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12733822
Heart Rate and Respiratory Rate Measurements from Imagery
3y 8m to grant Granted Sep 15, 2026
Patent 12722010
METHODS OF SELECTING PARAMETERS FOR THERAPEUTIC NEUROMODULATION
2y 9m to grant Granted Sep 01, 2026
Patent 12702837
DETERMINING ESTIMATED NEURAL THRESHOLD WITH ECAP SIGNALS
3y 1m to grant Granted Aug 11, 2026
Patent 12690797
AMBULATORY DETECTION OF QT PROLONGATION
3y 10m to grant Granted Jul 28, 2026
Patent 12690796
Wearable ECG and EDA with Multi-Lead and Single-Lead Connections
3y 7m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
78%
Grant Probability
88%
With Interview (+9.6%)
3y 3m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 876 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month